Cancer genetic testing
Cancer cells are abnormal cells in which certain genes become mutated or over-expressed. Normal cells become cancerous when there is a dysregulation or failure of the “oncogene” (the accelerator that causes cancer growth) or the “cancer suppressor gene” (the brakes that suppress cancer growth) in the cell.
By investigating which genes have mutations or abnormalities through cancer genetic testing, it is possible to select drugs and treatments that are most effective for mitigating the effects of or repairing such genes and to predict prognosis.
Incorporating cancer genetic testing before and after treatment enables the characteristics of each individual patient’s cancer to be understood at the genetic level. The progress and effects of the treatment can be specifically recognized, and provides feedback so that the doctor and patient can devise a logical treatment plan based on scientific evidence.
Genetic testing detects genetic changes in cancer cells at a very early stage, including cancers that are 5mm or less in size (prior to visualization by imaging studies) and also may test pre-cancerous lesions. Thus, using these early detection techniques can help not only to prevent the recurrence of cancer but also to prevent primary cancer development for those who have not yet been diagnosed.
Approximately 21ml of venous blood is collected. Analysis is conducted in a licensed clinical laboratory. Results are ready in about 3 weeks, and test results are explained by a physician, where the therapeutic effect, prognosis, and future treatment plan can be discussed.